Dexamethasone suppresses long QT phenotype in patient with acute promyelocytic leukemia treated with arsenic  by Winterfield, Jeffrey R. & Milan, David J.
Dexamethasone suppresses long QT phenotype in patient
with acute promyelocytic leukemia treated with arsenic
Jeffrey R. Winterﬁeld, MD, FHRS,* David J. Milan, MD†
From the *Department of Cardiology, Section of Clinical Cardiac Electrophysiology, Loyola University
Medical Center, Maywood, Illinois, and †Cardiovascular Research Center, Clinical Cardiac
Electrophysiology, Massachusetts General Hospital, Charlestown, Massachusetts.Introduction
Arsenic trioxide has recently been found to improve survival
and complete response when added to all-trans retinoic acid
(ATRA) for the treatment of acute promyelocytic leukemia
(APL). However, dose-limiting toxicity in the form of drug-
induced QT prolongation limits its use in a signiﬁcant
percentage of patients.1
Preclinical models of long QT syndrome (LQTS) have
demonstrated that glucocorticoids can signiﬁcantly shorten
the duration of the cardiac action potential.2 However, the
relevance of these ﬁndings is unclear in human populations.
Here we report the protective effects of glucocorticoid
administration on QT interval in a case of APL treated with
arsenic trioxide.Case report
A 38-year-old woman who was 21 weeks gravid presented
with APL. Her symptoms at presentation included headache,
dyspnea, and lower-extremity edema. Her white cell count
was elevated (11.9) with coagulation test results consistent
with disseminated intravascular coagulation; these ﬁndings
placed her in a high-risk category. Termination of the
pregnancy was initially recommended, but the patient
declined this course of action. Her electrocardiogram
recorded at presentation showed a corrected QT interval
(QTc) of 508 milliseconds, which suggested that an abnor-
mal repolarization reserve existed even before the admin-
istration of any QT-prolonging medications (Figure 1A). NoKEYWORDS Arsenic; Cardio-oncology; ECG; Leukemia; Long QT syndrome
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The patient received high-dose ATRA on day 1, followed
by induction chemotherapy with daunorubicin. Ordinarily,
arsenic trioxide would have been administered at this time,
but it was withheld because of the 100% risk of fetal demise.
She developed retinoic acid or differentiation syndrome,3
and she required a brief stay in the intensive care unit, for
respiratory distress. Dexamethasone was administered for
management of nausea and retinoic acid syndrome during
induction chemotherapy, and we fortuitously observed a
QTc reduction to approximately 478 milliseconds
(Figure 1B). A review of her medications at this point in
her hospitalization did not reveal any identiﬁable QT-
prolonging agents. Her electrolyte levels remained within
the normal range.
The patient recovered and continued ATRA therapy.
Following induction chemotherapy, a bone marrow biopsy
demonstrated leukemia remission with normal cytogenetic
results. The patient remained pregnant, and consolidation
therapy with idarubicin plus ATRA was continued from July
24, 2013, to September 19, 2013. Shortly after delivery of a
full-term, healthy male neonate (Apgar scores 9/9/9), the
patient began consolidation therapy with arsenic trioxide, but
the ﬁrst cycle was discontinued prematurely because of a
QTc prolongation of approximately 581 milliseconds, which
required inpatient monitoring (Figure 2A). No other QT-
prolonging medications had been administered during this
period, and the QT interval returned toward normal after the
arsenic was discontinued (October 28 and November 4,
respectively). The patient was referred to the electrophysi-
ology (EP) department for management recommendations
and facilitation of continued arsenic trioxide administration.
During the index EP visit on November 5, 2013, the
patient’s QTc measured approximately 481 milliseconds.
Genetic testing for LQTS was ordered, and the test results
eventually returned without abnormal ﬁndings. Given the
beneﬁt of arsenic trioxide to her survival, she was admi-
tted to the hospital for QT monitoring during the ﬁrst week
of a second cycle of arsenic therapy. Within 2 days of
starting arsenic treatment, the QTc again became markedlypen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Treatment of acute promyelocytic leukemia with
all-trans retinoic acid can be associated with
dangerous levels of QT prolongation. The QT
interval should be monitored in patients receiving
this therapy.
 Glucocorticoid treatment of patients who have
drug-induced QT prolongation may limit or reverse
the QT prolongation.
 This case and another similar report suggest that
glucocorticoid treatment in the setting of drug-
induced QT prolongation may be beneﬁcial. This
observation is worthy of further investigation,
although data are insufﬁcient to make
recommendations regarding patient care at
this time.
281Winterﬁeld et al Dexamethasone Suppression of Long QT Syndromeprolonged, to 540 milliseconds. Starting on day 3 of
hospitalization, we initiated high-dose dexamethasone (10
mg twice a day). The QTc decreased substantially within the
ﬁrst day of administration, to 457 milliseconds (Figure 2B).Figure 1 A: A baseline electrocardiogram, recorded at presentation, with QTc p
or other potential QT-prolonging agents. B: An electrocardiogram recorded Jun
administered for nausea, and we observed QTc reduction to 478 milliseconds.There were no changes in serum electrolyte levels over that
same period.
The patient remained in the hospital for the remainder of
the week for completion of the ﬁrst cycle of arsenic. She was
then ﬁtted with a LifeVest (ZOLL Medical, Chelmsford,
MA) and discharged to her home for the completion of
outpatient administration of arsenic. The recorded QTc
intervals and their correlation with arsenic and dexametha-
sone treatment are shown in Figure 3.
Discussion
We present a case of drug-induced LQTS with arsenic
trioxide in which the patient was coincidentally treated with
high-dose dexamethasone. Treatment with high-dose dex-
amethasone was repeatedly associated with a decrease in the
QT interval that was reversible upon cessation of treatment.
In this particular case, circulating cytokines due to the APL
itself might be perturbing the cardiomyocyte physiology,4
and dexamethasone might mitigate these effects. Alterna-
tively, the induction of serum and glucocorticoid kinase has
been shown to raise human ether-a-gogo–related gene
(hERG) protein expression levels and might mitigate QT
prolongation.5 Thus, the relevance of this ﬁnding to other
forms of drug-induced or genetic LQTS remains unknown.rolongation measuring 508 milliseconds prior to administration of arsenic
e 29, 2013, after dexamethasone reduces QTc. Dexamethasone had been
Figure 2 A:Marked correct QT (QTc) prolongation to 581 milliseconds during the ﬁrst cycle of consolidation chemotherapy with arsenic, which resulted in
therapy discontinuation and inpatient admission for monitoring. The QTc returned to baseline following the cessation of arsenic treatment. B: Rescue of arsenic-
triggered QTc prolongation with dexamethasone. QTc measurements (blue bars indicate measurement points) during arsenic administration before and after
administration of high-dose dexamethasone.
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to shorten the ventricular action potential duration in an
animal model of genetic LQTS, but its mechanism of action
is unknown.2 In addition, treatment with prednisolone has
been reported to correct QT prolongation in the setting of
sodium stibogluconate therapy of mucocutaneous leishma-
niasis, although the glucocorticoid was not repetitivelyFigure 3 Corrected QT (QTc) measurements during treatment with
arsenic and dexamethasone. Temporal declines in QTc correlated with
cessation of arsenic therapy and also with dexamethasone treatment.given, as it was in this case.6 While the side effect proﬁle
of high-dose glucocorticoids would prevent long-term treat-
ment of patients with a genetic form of LQTS, shorter-term
treatment to enable life-saving therapies, such as in this case,
merit further investigation.
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